Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial

INTRODUCTION: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been shown to have beneficial effects on various cardiovascular (CV) outcomes in patients with type 2 diabetes (T2D) in primary prevention and in those with a high CV risk profile. However, the mechanism(s) responsible for these...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorice, Gian Pio, Cinti, Francesca, Leccisotti, Lucia, D’Amario, Domenico, Lorusso, Margherita, Guzzardi, Maria Angela, Mezza, Teresa, Cocchi, Camilla, Capece, Umberto, Ferraro, Pietro Manuel, Crea, Filippo, Giordano, Alessandro, Iozzo, Patricia, Giaccari, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266960/
https://www.ncbi.nlm.nih.gov/pubmed/34037951
http://dx.doi.org/10.1007/s13300-021-01083-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266960/
https://www.ncbi.nlm.nih.gov/pubmed/34037951
http://dx.doi.org/10.1007/s13300-021-01083-1

Ejemplares similares